Clinical Trial Update: Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing ART-123 in adults with severe sepsis and coagulopathy has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coagulopathy
• Sepsis

Drugs mentioned

• ART-123 (recombinant human soluble thrombomodulin)

Snippet

Sponsor: Asahi Kasei Pharma America Corporation | Conditions: Severe Sepsis, Coagulopathy | Phase 3 | Status: COMPLETED | Results posted: 2020-04-21